What were Astec Lifesciences Ltd's latest quarterly results?
Astec Lifesciences Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +60.0%
- Revenue Growth YoY: +33.0%
- Operating Margin: 3.0%
Astec Lifesciences Ltd (Pesticides/Agrochemicals) — fundamental analysis, earnings data, and key metrics. ROE: -45.3%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Astec Lifesciences Ltd's latest quarterly results (Dec 2025) show
Astec Lifesciences Ltd's price-to-book ratio is 3.1x.
Astec Lifesciences Ltd's fundamental strength based on key financial ratios
Astec Lifesciences Ltd has a debt-to-equity ratio of N/A.
Astec Lifesciences Ltd's return ratios over recent years
Astec Lifesciences Ltd's operating cash flow is negative (FY2025).
Astec Lifesciences Ltd currently does not pay a significant dividend (yield 0.00%).
Astec Lifesciences Ltd's shareholding pattern (Dec 2025)
Astec Lifesciences Ltd's promoter holding has decreased recently.
Astec Lifesciences Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Astec Lifesciences Ltd may be worth studying
Astec Lifesciences Ltd investment thesis summary:
Astec Lifesciences Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.